Evaluation and Impact of Biosimilars: Perceptions from Payer and Health-System Experts

Our recent Primary Market Insights report summarizes insights from over 110 regional and national payer and health-system experts regarding biosimilar management strategy, the financial impact of biosimilars, and interchangeability. With input from vice presidents of pharmacy, pharmacy directors, clinical pharmacists, and purchasing/operations executives, the report examines how organizations are measuring biosimilar savings, planning for preferred products, covering Humira biosimilars, and reacting to price changes on long-acting insulin glargine products, and more.